The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease
2018年8月14日 - 10:30PM
JCN Newswire
Collaboration will harness AI technology to address an
aging-related target
NOVATO, US, 2018年8月14日 - (Media OutReach) - The Buck Institute for
Research on Aging, Insilico Medicine, and Juvenescence Ltd
announced today that they have formed Napa Therapeutics, Ltd to
develop drugs against a novel aging-related target. The Buck
Institute is one of the leading research centers in the world
focused solely on research on aging and the elimination of
age-related disease. Insilico Medicine is an AI company focused on
a range of verticals devoted to aging. Insilico Medicine stands to
earn more than $100M in milestone payments should the program be
successful. Juvenescence is a company focused on developing drugs
to modify aging and the diseases of aging.
Napa Therapeutics is based on groundbreaking research in NAD
metabolism conducted in the lab of Eric Verdin, MD, President and
CEO of the Buck Institute. The Verdin lab will collaborate with
Napa, using Insilico's drug development engine to speed the
discovery of new compounds. "This is a unique opportunity to use
cutting-edge AI to accelerate drug discovery," said Dr. Verdin.
"The Buck is excited to join forces with Insilico and Juvenescence
as we work to eliminate the threat of age-related disease for this
and future generations."
"I am most excited by this model and the ability to combine the
quality science of the Buck Institute with the remarkable deep
learning engine at Insilico Medicine. To me this is another big
step in the evolving process of using AI with HI (human
intelligence) to extract the best of both systems," said Gregory
Bailey, MD, CEO of Juvenescence. "Napa Therapeutics lets
Juvenescence deepen our collaboration with the Buck Institute and
with Insilico Medicine. We hope to shorten the time required to
identify molecules that can be brought to the clinic and most
importantly help patients."
"We are very happy to partner with the Buck Institute and
Juvenescence around a very promising set of targets in a pathway
overlooked by the pharmaceutical industry. Aging research is among
the most altruistic causes that will improve and extend the lives
of everyone on the planet and reduce the pain and suffering
associated with the age-associated diseases. However, in order to
scale, our efforts must become sustainable and provide reasonable
returns to investors. If successful, Insilico Medicine alone stands
to earn in excess of $100 million in milestone payment from this
deal", said Alex Zhavoronkov, PhD, founder and CEO of Insilico
Medicine.
About Napa Therapeutics. Ltd
Napa Therapeutics, Ltd. is a biotechnology company focused on a
novel target linked to one of the fundamental processes of aging. A
privately held British Virgin Islands company with an office in the
Isle of Man, Napa is developing small molecule drugs to address
this target.
About the Buck Institute for Research on Aging
Our success will ultimately change healthcare. At the Buck, we aim
to end the threat of age-related diseases for this and future
generations by bringing together the most capable and passionate
scientists from a broad range of disciplines to identify and impede
the ways in which we age. An independent, nonprofit institution,
our goal is to increase human health span, or the healthy years of
life. Globally recognized as the pioneer and leader in efforts to
target aging, the number one risk factor for serious diseases
including Alzheimer's, Parkinson's, cancer, macular degeneration,
heart disease, and diabetes, the Buck wants to help people live
better longer. Learn more at: https://buckinstitute.org
About Juvenescence, Ltd.
Juvenescence Limited is a company focused on developing therapies
and drugs to increase human longevity and complementary investments
in related sectors. It was founded in 2017. The Juvenescence team
are highly experienced entrepreneurs and drug developers focused on
life science and commercial drug development. Juvenescence creates
new ventures and invests time and money directly in both start-up
and in conjunction with established longevity related companies
offering operational support.
Juvenescence believes that advances in science have made real the
possibility of slowing, halting or potentially reversing some
elements of ageing and is assembling a pipeline of therapeutic
agents through joint ventures.
About Insilico Medicine, Inc.
Insilico Medicine is an artificial intelligence company with
R&D offices and resources in the US, Belgium, Russia, the UK,
Taiwan and Korea, sourced through hackathons and competitions. The
company and its scientists are dedicated to extending human
productive longevity and transforming every step of the drug
discovery and drug development process through excellence in
biomarker discovery, drug development, digital medicine and aging
research.
Insilico pioneered the applications of the generative adversarial
networks (GANs) and reinforcement learning for generation of novel
molecular structures for diseases with a known ligand and with no
known targets. In addition to working collaborations with large
pharmaceutical companies, the company is pursuing internal drug
discovery programs in cancer, dermatological diseases, fibrosis,
Parkinson's Disease, Alzheimer's Disease, ALS, diabetes,
sarcopenia, and aging. Through a partnership with LifeExtension.com
the company launched a range of nutraceutical products, compounded
using advanced bioinformatics and deep learning techniques. It also
provides a range of consumer-facing applications, including
Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI
companies for potential in social impact. In 2018, the company was
named one of the global top 100 AI companies by CB Insights. In
2018 it received the Frost & Sullivan 2018 North American
Artificial Intelligence for Aging Research and Drug Development
Award accompanied by industry brief. Brief company video:
https://www.youtube.com/watch?v=l62jlwgL3v8.
http://www.insilico.com
Contact Information:
Roger Lai, Consultant
jclai@swem.com.tw
Source: Insilico Medicine, Inc.
Copyright 2018 JCN Newswire . All rights reserved.